<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02295514</url>
  </required_header>
  <id_info>
    <org_study_id>2014/087/HP</org_study_id>
    <nct_id>NCT02295514</nct_id>
  </id_info>
  <brief_title>Correlation Between PTP1B Expression and Organ Failure During Sepsis</brief_title>
  <acronym>SEPP1B</acronym>
  <official_title>Correlation Between PTP1B Expression and Organ Failure During Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite major advances in the treatment and understanding of the pathophysiological
      mechanisms, mortality of severe sepsis remains high, ranging from 25 to 50%. With a
      prevalence &gt; 20% in intensive care units, it is now in a population increasingly aging with
      many co-morbidities, a real public health problem. Thus, changes in treatment to
      physiological axes could change the prognosis of these patients. Protein Tyrosine Phosphatase
      1B (PTP1B) is involved in the negative regulation of many cellular pathways such as the
      response to insulin, leptin and certain growth factors and endothelial nitric oxide
      production. PTP1B appears to be particularly involved in the control of endothelial function
      and insulin secretion. Under these conditions, encouraging results have been obtained in a
      model of insulin resistance (obesity, diabetes) and as part of pro-angiogenic therapy by
      inhibition of PTP1B on models of heart failure. Recent advances have broadened the
      pathophysiological implications of PTP1B conferring a potential role in the regulation of
      inflammatory processes. In an experimental model of septic shock (Inserm 1096), the
      investigators demonstrated a significant improvement in survival and cardiovascular function
      in genetically deficient mice PTP1B (PTP1B - / -). Finally, PTP1B is involved in the
      downregulation of the signaling pathway of insulin via a feedback phenomenon. Septic shock
      induces many changes in carbohydrate metabolism. These changes result in hyperglycemia
      associated with insulin resistance, an independent risk factor of morbidity and mortality.
      Taken together, these data suggest that the expression of PTP1B could be useful in septic
      patients by modulating insulin resistance and thus the prognosis of these patients. This
      justifies the investigator clinical research project on the relationship between the
      expression of PTP1B levels, glycemic status and prognosis evaluated by the SOFA score in
      patients with septic shock with multiple organ failure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in PTP1B level expression</measure>
    <time_frame>Day 5</time_frame>
    <description>Change from baseline in PTP1B level expression by biological analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with organ failure</measure>
    <time_frame>Day 5</time_frame>
    <description>Number of patients with organ failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose of insulin administered during the sepsis</measure>
    <time_frame>Day 5</time_frame>
    <description>cumulative dose of insulin administered in the first 5 days of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance evaluation</measure>
    <time_frame>Day 1</time_frame>
    <description>Evaluation of insulin resistance by biological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose Analysis</measure>
    <time_frame>Day 5</time_frame>
    <description>Analysis of the variability in Blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of death participants at ICU discharge</measure>
    <time_frame>ICU discharge, day 28</time_frame>
    <description>ICU mortality at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of death participants at at the end of the study</measure>
    <time_frame>Day 28</time_frame>
    <description>Mortality at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of death participants at at hospital discharge</measure>
    <time_frame>10 days (average)</time_frame>
    <description>Mortality at hospital discharge, average of 10 days after surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Duration of mechanical ventilation from admission to discharge</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>PTP1B dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTP1B dosage during sepsis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PTP1B dosage</intervention_name>
    <description>PTP1B sampled and dosed during sepsis</description>
    <arm_group_label>PTP1B dosage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in ICU for septic shock

          -  Person belonging to a social security system

          -  Informed patient who signed consent

          -  Contraceptive method in women of reproductive age

        Exclusion Criteria:

          -  Pregnancy

          -  Patient not able to take a decision because of an administrative or legal decision

          -  Patient participating to an other interventional study

          -  BMI &gt; 30 kg/m2

          -  Diabetes with specific treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>steven grangé, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen Universitary Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML, Kennedy BP. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999 Mar 5;283(5407):1544-8.</citation>
    <PMID>10066179</PMID>
  </reference>
  <reference>
    <citation>Coquerel D, Neviere R, Delile E, Mulder P, Marechal X, Montaigne D, Renet S, Remy-Jouet I, Gomez E, Henry JP, do Rego JC, Richard V, Tamion F. Gene deletion of protein tyrosine phosphatase 1B protects against sepsis-induced cardiovascular dysfunction and mortality. Arterioscler Thromb Vasc Biol. 2014 May;34(5):1032-44. doi: 10.1161/ATVBAHA.114.303450. Epub 2014 Feb 27.</citation>
    <PMID>24578383</PMID>
  </reference>
  <reference>
    <citation>Través PG, Pardo V, Pimentel-Santillana M, González-Rodríguez Á, Mojena M, Rico D, Montenegro Y, Calés C, Martín-Sanz P, Valverde AM, Boscá L. Pivotal role of protein tyrosine phosphatase 1B (PTP1B) in the macrophage response to pro-inflammatory and anti-inflammatory challenge. Cell Death Dis. 2014 Mar 13;5:e1125. doi: 10.1038/cddis.2014.90.</citation>
    <PMID>24625984</PMID>
  </reference>
  <reference>
    <citation>Zabolotny JM, Kim YB, Welsh LA, Kershaw EE, Neel BG, Kahn BB. Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem. 2008 May 23;283(21):14230-41. doi: 10.1074/jbc.M800061200. Epub 2008 Feb 14.</citation>
    <PMID>18281274</PMID>
  </reference>
  <reference>
    <citation>Ali MI, Ketsawatsomkron P, Belin de Chantemele EJ, Mintz JD, Muta K, Salet C, Black SM, Tremblay ML, Fulton DJ, Marrero MB, Stepp DW. Deletion of protein tyrosine phosphatase 1b improves peripheral insulin resistance and vascular function in obese, leptin-resistant mice via reduced oxidant tone. Circ Res. 2009 Nov 6;105(10):1013-22. doi: 10.1161/CIRCRESAHA.109.206318. Epub 2009 Sep 24.</citation>
    <PMID>19797171</PMID>
  </reference>
  <results_reference>
    <citation>Feldhammer M, Uetani N, Miranda-Saavedra D, Tremblay ML. PTP1B: a simple enzyme for a complex world. Crit Rev Biochem Mol Biol. 2013 Sep-Oct;48(5):430-45. doi: 10.3109/10409238.2013.819830. Epub 2013 Jul 23. Review.</citation>
    <PMID>23879520</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2014</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Septic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

